Toward the end of trading Wednesday, the Dow traded down 0.20 percent to 25,268.98 while the NASDAQ climbed 0.09 percent to 7,710.32. The S&P also fell, dropping 0.18 percent to 2,781.97.
Leading and Lagging Sectors
Wednesday afternoon, the consumer discretionary shares surged 0.58 percent. Meanwhile, top gainers in the sector included Turtle Beach Corporation HEAR up 13 percent, and Sears Holdings Corporation SHLD up 12 percent.
In trading on Wednesday, telecommunication services shares fell 3.2 percent.
Top Headline
Korn/Ferry International KFY reported upbeat results for its fourth quarter on Wednesday.
Korn/Ferry posted quarterly earnings of $0.80 per share on revenue of $488.364 million. However, analysts were expecting a loss of $0.70 per share on revenue of $458.38 million.
Korn/Ferry expects Q1 earnings of $0.67 to $0.75 per share on fee sales of $450 million to $470 million. Analysts project earnings of $0.66 per share on sales of $435.10 million.
Equities Trading UP
Enphase Energy, Inc. ENPH shares shot up 33 percent to $5.9948 in reaction to an acquisition announcement. The global energy technology company agreed to acquire SunPower Corporation SPWR's microinverter business for $25 million in cash and 7.5 million shares of Enphase common stock. The transaction also adds 140 new patents to Enphase's IP portfolio.
Shares of Pivotal Software, Inc. PVTL got a boost, shooting up 27 percent to $27.00 trading after reporting strong Q1 results. Pivotal Software posted Q1 adjusted loss of $0.10 per share on sales of $155.7 million.
Sharing Economy International Inc. SEII shares were also up, gaining 21 percent to $4.269. The China-based company that targets the global sharing economy markets said one of its wholly-owned subsidiary entered into a licensing agreement with Ecrent Capital to establish a website platform in North Korea.
Equities Trading DOWN
Flex Pharma, Inc. FLKS shares dropped 68 percent to $1.35 following a release from the company announcing the scrapping of two clinical trials and the exploration of strategic options. Flex Pharma is ending the ongoing Phase 2 clinical trials of its lead product candidate FLX-787, which was being investigated for both amyotrophic lateral sclerosis, or ALS, and Charcot-Marie-Tooth disorder, or CMT. Flex Pharma's board has constituted a strategic committee to evaluate strategic options, including a potential sale or merger of the company. The biotech is eliminating 60 percent of its workforce by June 30; while the restructuring will cost the company $800,000 to $1.11 million in one-time costs, it expects to reap annualized cost savings beginning in the third quarter.
Shares of scPharmaceuticals Inc. SCPH were down 22 percent to $5.968 after the company received a Complete Response Letter (CRL) from the FDA for FUROSCIX.
H&R Block, Inc. HRB was down, falling around 18 percent to $24.265. H & R Block reported better-than-expected earnings for its fourth quarter and raised its quarterly dividend from $0.24 per share to $0.25 per share.
Commodities
In commodity news, oil traded up 0.33 percent to $66.58 while gold traded up 0.17 percent to $1,301.60.
Silver traded up 0.59 percent Wednesday to $16.99, while copper rose 0.22 to $3.2565.
Eurozone
European shares closed mostly higher today. The eurozone’s STOXX 600 gained 0.19 percent, the Spanish Ibex Index fell 0.15 percent, while Italy’s FTSE MIB Index climbed 0.44 percent. Meanwhile the German DAX climbed 0.38 percent, and the French CAC 40 fell 0.01 percent while U.K. shares fell 0.01 percent.
Economics
The Producer Price Index rose 0.5 percent for May, versus economists’ expectations for a 0.3 percent increase.
Crude supplies declined 4.1 million barrels for the week ended June 8, the U.S. Energy Information Administration reported. However, analysts were expecting a drop of 2.6 million barrels. Gasoline stockpiles fell 2.3 million barrels, while distillate stockpiles dropped 2.1 million barrels for the week.
The Federal Reserve increased its benchmark rate by a quarter-percentage point to a range of 1.75 percent to 2 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.